This has led to the discovery of novel autoantibodies, including novel anti-aminoacyl-tRNA synthetase autoantibodies and autoantibodies which modify cancer risk for patients with anti-TIF1ɣ associated dermatomyositis. This evidence concerns the gene TRIM24 and cancer.